48 results
S-3ASR
DNLI
Denali Therapeutics Inc
22 Mar 24
Automatic shelf registration
4:01pm
;
the impact of increased geopolitical uncertainty, the COVID-19 pandemic, and related global economic disruptions and social conditions on our business
8-K
EX-99.1
gbw5n8kq d9a02
8 May 23
Denali Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
4:03pm
8-K
EX-99.1
8y3x12slsm90v4
3 Nov 22
Denali Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
4:05pm
424B5
kqj0c39vxnvdhjk0j
20 Oct 22
Prospectus supplement for primary offering
4:57pm
8-K
EX-99.3
m6dvs
18 Oct 22
Denali Therapeutics Announces Proposed Offering of Common Stock
5:09pm
424B5
x000k1z
18 Oct 22
Prospectus supplement for primary offering
5:08pm
8-K
EX-99.1
7pqp423z77msi6c84g
8 Aug 22
Denali Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
4:03pm
8-K
EX-99.1
jn4onmgn22llnvmz8
5 May 22
Denali Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
4:03pm
S-3ASR
qr58 q11m4
28 Feb 22
Automatic shelf registration
5:26pm
8-K
EX-99.1
nk63p1 7zkt0y68
28 Feb 22
Denali Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights
4:04pm